Vaccine Doubts Hit Sentiment
Thursday’s session was quiet owing to most traders sitting on their hands given the Thanksgiving holiday in the US. Whilst the US markets are open for a half day, we’re not expecting much in the way of volume. Black Friday shopping is also offering another distraction.
Share this:
Thursday’s session was quiet owing to most traders sitting on their hands given the Thanksgiving holiday in the US. Whilst the US markets are open for a half day, we’re not expecting much in the way of volume. Black Friday shopping is also offering another distraction.
European bourses are edging lower, as the vaccine optimism seen at the start of the week has completely fizzled now that questions are growing over the soundness of the AstraZeneca covid vaccine trial. The doubts could delay the cheap and easily transported vaccine from being approved quickly by regulators.
The pharmaceutical giant is likely to run a new additional study to assess the efficacy of a lower dosage after a subgroup which accidentally received an initial half dose revealed the dose to be 90% effective. AstraZeneca share are trading 1% lower.
Chinese factory profits soar
Concerns over the vaccine are overshadowing news that Chinese industrial profits surged at the fastest pace since early 2017. Although the minrers are finding support from the knowledge that the recovery in the world’s largest consumer of metals was powering along nicely. This is a stark contrast to Europe and the US which are still battling to bring covid infections under control.
Concerns over the vaccine are overshadowing news that Chinese industrial profits surged at the fastest pace since early 2017. Although the minrers are finding support from the knowledge that the recovery in the world’s largest consumer of metals was powering along nicely. This is a stark contrast to Europe and the US which are still battling to bring covid infections under control.
UK’s gloomy outlook
The British government yesterday announced the UK Tier breakdown for when the national lockdown ends next week. With around 20 million Brits going from national lockdown to Tier 3, the toughest category the economic outlook for the UK remains particularly gloomy
The British government yesterday announced the UK Tier breakdown for when the national lockdown ends next week. With around 20 million Brits going from national lockdown to Tier 3, the toughest category the economic outlook for the UK remains particularly gloomy
Oil & gold struggle
Oil prices are declining on Friday in quiet trade amid concerns over oversupply and doubts over a vaccine to end the covid pandemic. Despite falling for a second straight session both Brent and WTI are on track to book gains in the region of 6% across the week.
Meanwhile, the risk off mood wasn’t helping gold, which continues to struggle for direction just north of $1800.
Oil prices are declining on Friday in quiet trade amid concerns over oversupply and doubts over a vaccine to end the covid pandemic. Despite falling for a second straight session both Brent and WTI are on track to book gains in the region of 6% across the week.
Meanwhile, the risk off mood wasn’t helping gold, which continues to struggle for direction just north of $1800.
FTSE Chart
After the FTSE’s strong run up at the start of the month on vaccine news, the rally has been consolidating in the horizontal channel of 6515 and 6325. The price is currently find support on the lower ban of the channel. A break through 6325 could open the door to a deeper selloff towards horizontal support at 6120 and then near 6000, the confluence of the 50,100 & 200 day moving average.
Should support at 6325 hold then the FTSE could make another push towards 6500.
Thursday’s session was quiet owing to most traders sitting on their hands given the Thanksgiving holiday in the US. Whilst the US markets are open for a half day, we’re not expecting much in the way of volume. Black Friday shopping is also offering another distraction.
European bourses are edging lower, as the vaccine optimism seen at the start of the week has completely fizzled now that questions are growing over the soundness of the AstraZeneca covid vaccine trial. The doubts could delay the cheap and easily transported vaccine from being approved quickly by regulators.
The pharmaceutical giant is likely to run a new additional study to assess the efficacy of a lower dosage after a subgroup which accidentally received an initial half dose revealed the dose to be 90% effective. AstraZeneca share are trading 1% lower.
Chinese factory profits soar
Concerns over the vaccine are overshadowing news that Chinese industrial profits surged at the fastest pace since early 2017. Although the minrers are finding support from the knowledge that the recovery in the world’s largest consumer of metals was powering along nicely. This is a stark contrast to Europe and the US which are still battling to bring covid infections under control.
Concerns over the vaccine are overshadowing news that Chinese industrial profits surged at the fastest pace since early 2017. Although the minrers are finding support from the knowledge that the recovery in the world’s largest consumer of metals was powering along nicely. This is a stark contrast to Europe and the US which are still battling to bring covid infections under control.
UK’s gloomy outlook
The British government yesterday announced the UK Tier breakdown for when the national lockdown ends next week. With around 20 million Brits going from national lockdown to Tier 3, the toughest category the economic outlook for the UK remains particularly gloomy
The British government yesterday announced the UK Tier breakdown for when the national lockdown ends next week. With around 20 million Brits going from national lockdown to Tier 3, the toughest category the economic outlook for the UK remains particularly gloomy
Oil & gold struggle
Oil prices are declining on Friday in quiet trade amid concerns over oversupply and doubts over a vaccine to end the covid pandemic. Despite falling for a second straight session both Brent and WTI are on track to book gains in the region of 6% across the week.
Meanwhile, the risk off mood wasn’t helping gold, which continues to struggle for direction just north of $1800.
Oil prices are declining on Friday in quiet trade amid concerns over oversupply and doubts over a vaccine to end the covid pandemic. Despite falling for a second straight session both Brent and WTI are on track to book gains in the region of 6% across the week.
Meanwhile, the risk off mood wasn’t helping gold, which continues to struggle for direction just north of $1800.
FTSE Chart
After the FTSE’s strong run up at the start of the month on vaccine news, the rally has been consolidating in the horizontal channel of 6515 and 6325. The price is currently find support on the lower ban of the channel. A break through 6325 could open the door to a deeper selloff towards horizontal support at 6120 and then near 6000, the confluence of the 50,100 & 200 day moving average.
Should support at 6325 hold then the FTSE could make another push towards 6500.
Related tags:
Latest market news
Open an account in minutes
Experience award-winning platforms with fast and secure execution, and enjoy tight spreads from 0.5 pts on FX and 0.3 pts on indices.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
EUR/USD, FTSE 100 Forecast: Two trades to watch 1507
EUR/USD rises after weaker US CPI, PPI up next. FTSE 100 falls as weak China GDP data hits miners.
FTSE 100, USD/JPY Forecast: Two trades to watch
FTSE eases modestly despite inflation unexpectedly holding steady. USD/JPY drifts lower ahead of the FOMC rate decision.
EUR/USD, FTSE 100 Forecast: Two trades to watch 21-05-26
EUR/USD slips below 1.16 as weak eurozone data weighs on sentiment. FTSE 100 slips as oil prices rebound and caution returns.
This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.
StoneX Financial Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the StoneX group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), StoneX Financial Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact StoneX Financial Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.
In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither StoneX Financial Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.
StoneX Financial Pte. Ltd. is not under any obligation to update this report.
Trading CFDs carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit www.forex.com/en-sg/terms-and-policies for the complete Risk Disclosure Statement.